Trp-P-2

01/01/2001 - "The present study, therefore, compared the effects of the food mutagen/carcinogen, 3-amino-1-methyl-5H-pyrido(4,3-b)indole (Trp-P-2), in fresh or frozen normal human peripheral lymphocytes with frozen lymphocytes from the same thalassemia patient. "

04/01/1987 - "Based on a result suggesting that the frequency of the Trp-P-2-sensitive persons in patients suffering from cancers at digestive tract is higher than in healthy persons when the sensitive person is defined as the person whose SCE frequency in peripheral lymphocytes induced by in vitro treatment with Trp-P-2 is more than 2 sigma above the mean of the SCEs of healthy population under the identical assay conditions. "
11/01/1987 - "In the mice given Trp-P-2, the incidences of liver tumors in the males were dose-dependent (12.5 mg/kg, 12%; 25 mg/kg, 18%), while those of malignant lymphoma varied within a range from 5 to 19%. "
06/01/1986 - "Skin squamous cell papillomas and carcinomas developed in 6 of 20 mice (30%) in Experiment 1 and in 3 of 19 mice (16%) in Experiment 2. In contrast, application of 2.0 mg of Trp-P-2 twice weekly for 52 weeks did not produce any skin tumors. "
11/01/1987 - "Statistical analysis revealed that the incidences of the liver tumor in the mice given Trp-P-1 or Trp-P-2 and those of lymphoma in the mice given Trp-P-1 were significantly higher than those of the controls. "
08/01/1993 - "Histologically, tumors induced by Trp-P-2 were hepatocellular adenomas, transitional cell tumors (papillomas and carcinomas) of the urinary bladder, fibroadenomas/fibromas of the mammary gland, malignant lymphomas and clitoral gland tumors (adenomas and adenocarcinomas). "

09/01/1992 - "The number of chromosome aberrations induced by UV and MMC were increased by post-treatment with Trp-P-1 and Trp-P-2, in both the presence and the absence of S9 mix. "
01/01/1984 - "In excision repair-deficient CHO cells, Trp-P-2 exposure caused cytotoxicity, mutagenicity (thioguanine and azaadenine resistances), sister chromatid exchange, and chromosomal aberrations at concentrations more than 30-fold lower than those for IQ. "
09/01/1992 - "Trp-P-1, Trp-P-2, A alpha C, MeA alpha C and Glu-P-1 were weak clastogens by themselves, but at much higher concentrations than those at which they increased the induction of chromosome aberrations in cells pretreated with UV or MMC. "
11/01/1991 - "Intraperitoneal injections of Trp-P-1, Glu-P-1, MeIQx, IQ and nitro-IQ resulted in chromosome aberrations in up to 16% of the metaphase cells and SCEs at up to 0.9 per chromosome, while injections of Trp-P-2 and Glu-P-2 produced SCEs at up to 0.7 and 1.1 per chromosome, respectively. "

01/01/1985 - "There was a greater reduction in viable cell concentration in the xeroderma pigmentosum group A and D cells than in the normal lymphoblastoid cell lines after treatment with activated Trp-P-2. "
01/01/1985 - "These data suggest that the xeroderma pigmentosum DNA-repair system is defective in repairing Trp-P-1 and Trp-P-2 induced DNA damage in addition to being defective in repairing ultraviolet-induced DNA damage. "
01/01/1985 - "All xeroderma pigmentosum lymphoblastoid cell lines showed a greater reduction in viable cell concentration than the 2 normal lymphoblastoid cell lines following addition of Trp-P-1 or Trp-P-2 (5 micrograms/ml) to the culture medium. "
12/01/1983 - "Defective repair of tryptophan pyrolysate (Trp P-1 and Trp P-2) and aflatoxin B1 damage in xeroderma pigmentosum cells."

06/01/1986 - "Skin squamous cell papillomas and carcinomas developed in 6 of 20 mice (30%) in Experiment 1 and in 3 of 19 mice (16%) in Experiment 2. In contrast, application of 2.0 mg of Trp-P-2 twice weekly for 52 weeks did not produce any skin tumors. "
08/01/1993 - "Histologically, tumors induced by Trp-P-2 were hepatocellular adenomas, transitional cell tumors (papillomas and carcinomas) of the urinary bladder, fibroadenomas/fibromas of the mammary gland, malignant lymphomas and clitoral gland tumors (adenomas and adenocarcinomas). "